EMA’s PRAC to review Xeljanz and recommends fenspiride withdrawl
The committee has announced its latest meeting highlights.
Read More
Tag: fenspiride
EMA suspends fenspiride medicines due to heart rhythm risks
The EMA has announced an EU-wide suspension of fenspiride medicines due to a potential risk of heart rhythm problems.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
